CTI has been developing our expertise in immunology since inception.

With more than half of our recent projects deeply rooted in immunological indications, we bring a huge reservoir of immunology expertise to these programs

Immunology is a complex area of research encompassing diverse patient populations and products that target various aspects of the immune response. CTI has led multi-national development programs that have resulted in dozens of marketing approvals across the spectrum of immunology research, including therapeutics and devices. We understand the challenges associated with drug development in these complex and critically ill patient populations.

Immuno-oncology is the frontier of personalize medicine, and it is an area CTI excels in. Approximately 30% of CTI's most recent programs are in oncology and cell therapy, and over half of our recent projects are deeply rooted in immunological indications. Our approach has stayed true to our therapeutic focus and clinical trial expertise. We focus in complex and critically ill patient populations, bringing a huge reservoir of immunology and cellular therapy expertise to these programs.

We offer our sponsors:

Some of our adult and pediatric experience includes:

Specific areas:

  • Adenovirus
  • Autoimmune hepatitis
  • BK/Polyomavirus
  • Bacterial meningitis
  • Cardiac transplant
  • Crohn’s disease
  • Cytomegalovirus (CMV)
  • Fibrosis
  • Hepatitis B and C (HBV, HCV)
  • Human immunodeficiency virus (HIV)

  • Kidney transplant
  • Liver transplant
  • Lung transplant
  • Lymphoma
  • Lupus
  • Other autoimmune diseases
  • Pancreas transplant
  • Psoriasis
  • Rheumatoid arthritis (RA)
  • Stem cell/bone marrow transplant


  • Anti-fibrotic agents
  • Calcineurin inhibitors
  • Complement inhibitors
  • Co-stimulatory molecules
  • Immunoglobulins
  • Immunomodulators
  • Immunosuppressants
  • Induction therapies
  • Janus kinase (JAK) inhibitors

  • Mammalian target of rapamycin (mTOR) inhibitors
  • Monoclonal antibodies
  • Polyclonal antibodies
  • Polymerase inhibitors
  • Protease inhibitors
  • Ribonucleic acid (RNA) inhibitors
  • Toll receptors
  • Vaccines